Total Revenues of $11.3 Million Reported for the Third Quarter
Carticel and Epicel Revenues Increase 19% Compared to Third Quarter of 2014
Conference Call Today at 8:00am Eastern Time
CAMBRIDGE, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported financial results for the quarter ended September 30, 2015. Total revenues for the third quarter were generated primarily from net sales of Carticel® (autologous cultured chondrocytes) implants and surgical kits and Epicel® (cultured epidermal autografts), which were acquired on May 30, 2014 as part of the acquisition of Sanofi's cell therapy and regenerative medicine business.
Total revenues for the quarter ended September 30, 2015 were $11.3 million and included $7.7 million in net sales of Carticel implants and surgical kits and $3.3 million in net sales of Epicel. Total Carticel and Epicel net product revenues in the third quarter increased approximately 19% over third-quarter net product revenues in 2014. Epicel and Carticel net product revenues increased 83% and 4%, respectively, compared to the same period a year ago. For the nine months ended September 30, 2015, total Carticel and Epicel net product revenues were $35.1 million and increased 18% over pro-forma Carticel and Epicel net product revenues for the same period in 2014.
Gross profit for the quarter ended September 30, 2015 was $4.5 million, or 40% of total revenues. Gross profit for the quarter was reduced by 4% due to higher than normal inventory write-offs.
Research and development expenses for the quarter ended September 30, 2015 were $3.7 million versus $7.8 million for the same period a year ago. The decrease in third-quarter research and development expenses is primarily due to a reduction in expenses associated with the ongoing ixCELL-DCM clinical trial and a $3.2 million payment to Verigen shareholders in 2014 pursuant to a settlement agreement that eliminated all future milestone payments related to the development and commercialization of MACI™ (matrix-applied characterized autologous cultured chondrocytes) in the United States, partially offset by the addition of personnel and other expenses associated with Epicel, Carticel and MACI. MACI is Vericel's investigational third-generation autologous cultured chondrocyte implant for the treatment of symptomatic full-thickness cartilage defects of the knee.
Selling, general and administrative expenses for the quarter ended September 30, 2015 were $5.7 million compared to $4.3 million for the same period in 2014. The increase in SG&A expenses is primarily due to an increase in sales and marketing expenses associated with Carticel and Epicel as well as strategic planning activities for MACI.
Loss from operations for the quarter ended September 30, 2015 was $4.9 million compared to $8.0 million for the same period a year ago. Material non-cash items impacting the operating loss for the quarter included $0.6 million of stock-based compensation expense and $0.5 million in depreciation and amortization expense.
Other income for the quarter ended September 30, 2015 was $0.5 million compared to $1.1 million for the same period a year ago. The change in other income for the quarter is primarily due to the non-cash change in the fair value of warrants.
Vericel reported a net loss for the quarter ended September 30, 2015 of $4.4 million, or $0.26 per share, compared to a net loss of $6.9 million, or $0.82 per share, for the same period in 2014.
As of September 30, 2015, the company had $18.7 million in cash compared to $30.3 million in cash at December 31, 2014.
Recent Business Highlights
During and since the third quarter of 2015, the company:
- Increased total third-quarter Carticel and Epicel net product revenues by 19% versus net product revenues for the third quarter of 2014;
- Achieved 83% growth in Epicel net product revenues versus net product revenues for the third quarter of 2014;
- Announced plans to submit a Humanitarian Device Exemption (HDE) supplement to the FDA in the fourth quarter of 2015 to revise the labeled indications for use of Epicel to specifically include pediatric patients and to add pediatric labeling for Epicel;
- Continued to prepare a Biologics License Application (BLA) for submission by the end of 2015 for MACI for the treatment of focal chondral cartilage defects in the knee;
- Announced the execution of a long-term supply agreement with Matricel GmbH for the ACI-Maix collagen membrane used in the manufacture of MACI; and
- Continued to evaluate patients in the ongoing Phase 2b ixCELL-DCM clinical trial of ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
"Vericel continued to generate strong revenue growth during the third quarter, which reflects the success of our commercial initiatives," said Nick Colangelo, Vericel's president and chief executive officer. "We also made substantial progress in advancing our upcoming regulatory submissions for MACI and Epicel. These important initiatives have the potential to significantly expand our cartilage repair and burn therapy franchises and position the company for continued strong growth in the years ahead."
Conference Call Information
Today's conference call will be available live at 8:00am Eastern time in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation's third-quarter 2015 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events.cfm until Monday, November 14, 2016. A replay of the call will also be available until 11:59 pm (EST) on November 17, 2015 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 71018424.
About Vericel Corporation
Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the U.S.: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.
This document contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding the commercial potential of our products, revenue trends, intended product development, clinical activity timing and regulatory pathway and timing, integration of the acquired business, and objectives and expectations regarding our company described herein, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "can continue," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, integration of the acquired business, clinical trial and product development activities, regulatory approval requirements, the availability and allocation of resources among different potential uses, estimating the commercial potential of our products and product candidates and growth in revenues and improvement in costs, market demand for our products, and our ability to supply or meet customer demand for our products. These and other significant factors are discussed in greater detail in Vericel's Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission ("SEC") on March 25, 2015, Quarterly Reports on Form 10-Q and other filings with the SEC. These forward-looking statements reflect management's current views and Vericel does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|(Unaudited, amounts in thousands)|
|September 30,||December 31,|
|Accounts receivable (net of allowance for doubtful accounts of $54 and $40, respectively)||7,639||8,191|
|Other current assets||514||1,036|
|Total current assets||28,516||41,490|
|Property and equipment, net||4,315||2,892|
|LIABILITIES AND SHAREHOLDERS' EQUITY|
|Total current liabilities||9,261||11,829|
|Long term debt||81||109|
|Other long-term liabilities||66||—|
|COMMITMENTS AND CONTINGENCIES|
|Series B-2 voting convertible preferred stock, no par value: shares authorized and reserved — 39, shares issued and outstanding — 12||38,389||38,389|
|Common stock, no par value; shares authorized — 75,000; shares issued and outstanding — 23,789 and 23,786, respectively.||307,207||305,008|
|Other comprehensive loss||(71)||(71)|
|Total shareholders' equity||26,410||35,641|
|Total liabilities and shareholders' equity||$35,818||$47,579|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(Unaudited, amounts in thousands except per share amounts)|
|Three Months Ended September 30,||Nine Months Ended September 30,|
|Costs and expenses:|
|Cost of product sales||6,772||5,532||19,241||10,541|
|Research and development||3,740||7,835||11,486||15,470|
|Selling, general and administrative||5,674||4,313||16,735||9,267|
|Total operating expenses||9,414||12,148||28,221||24,737|
|Loss from operations||(4,877)||(8,022)||(11,714)||(21,188)|
|Other income (expense):|
|Decrease (increase) in fair value of warrants||461||949||256||(155)|
|Bargain purchase gain||—||—||—||3,634|
|Foreign currency translation gain (loss)||(5)||154||5||154|
|Total other income (expense)||461||1,105||284||3,638|
|Net loss per share attributable to common shareholders (Basic and Diluted)||$(0.26)||$(0.82)||$(0.69)||$(2.90)|
|Weighted average number of common shares outstanding (Basic and Diluted)||23,788||10,273||23,786||7,569|
CONTACT: Chad Rubin The Trout Group email@example.com (646) 378-2947 or Lee Stern The Trout Group firstname.lastname@example.org (646) 378-2922